title: Review of consensus interferon in the treatment of chronic hepatitis C.
abstract: Consensus interferon (CIFN) is an artificially engineered interferon that reflects most of the human genotype 1 interferons and shows a higher biological and antiviral capacity in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well established and recommended. Today patients are being treated with a combination therapy of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for patients with these genotypes along with either low viral load or early virological response, therapy for 24 weeks is sufficient. Patients with genotype 2 and 3 should be treated for up to 24 weeks. However, daily dosing of IFN-alpha, eg, CIFN, resulting in a higher cumulative dosage, might be beneficial and more efficacious in some chronic HCV-infected patients. Patients with genotype 1, having initially high viral load (>800,000 IU/mL) and showing advanced liver disease with progressive fibrosis or even cirrhosis comprise the difficult-to-treat in order to overcome the infection. This review summarizes and critically discusses the published data on the treatment of HCV with CIFN.
authors.affiliation: University Hospital Schleswig Holstein, Campus Lübeck, Dept of Medicine I, Division of Gastroenterology, Lübeck, Germany.
authors.forename: Th
authors.initials: T
authors.lastname: Witthöft
references.citation: Hepatology. 1997 Jul;26(1):226-31
references.pmid: 9214474
references.citation: Keio J Med. 2006 Sep;55(3):111-7
references.pmid: 17008803
references.citation: Liver Int. 2006 Apr;26(3):319-25
references.pmid: 16584394
references.citation: Rev Gastroenterol Disord. 2004;4 Suppl 1:S22-30
references.pmid: 15184821
references.citation: Am J Gastroenterol. 1999 Sep;94(9):2496-500
references.pmid: 10484014
references.citation: Am J Gastroenterol. 1999 Dec;94(12):3583-8
references.pmid: 10606323
references.citation: Am J Gastroenterol. 2000 Nov;95(11):3225-9
references.pmid: 11095346
references.citation: J Hepatol. 2006 Feb;44(2):291-301
references.pmid: 16360972
references.citation: J Viral Hepat. 2003 Jan;10(1):43-9
references.pmid: 12558911
references.citation: Turk J Gastroenterol. 2006 Mar;17(1):35-9
references.pmid: 16830275
references.citation: J Viral Hepat. 1998 Jul;5(4):271-6
references.pmid: 9751014
references.citation: Hepatology. 1999 Jul;30(1):271-6
references.pmid: 10385666
references.citation: J Endocrinol Invest. 2002 Jul-Aug;25(7):624-30
references.pmid: 12150338
references.citation: J Interferon Cytokine Res. 1996 Jul;16(7):489-99
references.pmid: 8836913
references.citation: Curr Gastroenterol Rep. 2002 Feb;4(1):23-30
references.pmid: 11825538
references.citation: Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S
references.pmid: 9305673
references.citation: Cytokines Cell Mol Ther. 1999 Dec;5(4):211-6
references.pmid: 10850385
references.citation: J Gastroenterol Hepatol. 2000 Dec;15(12):1418-23
references.pmid: 11197053
references.citation: Gastroenterology. 2004 Apr;126(4):1015-23; discussion 947
references.pmid: 15057741
references.citation: J Clin Gastroenterol. 2004 Aug;38(7):599-604
references.pmid: 15232365
references.citation: Dig Dis Sci. 2007 Jun;52(6):1540-7
references.pmid: 17406822
references.citation: Cytokines Cell Mol Ther. 1999 Dec;5(4):207-10
references.pmid: 10850384
references.citation: Nat Clin Pract Gastroenterol Hepatol. 2007 Jan;4 Suppl 1:S3-9
references.pmid: 17235282
references.citation: J Viral Hepat. 2003 Jan;10(1):55-60
references.pmid: 12558913
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: J Viral Hepat. 2002 Sep;9(5):334-9
references.pmid: 12225327
references.citation: Hepatology. 1997 Sep;26(3):747-54
references.pmid: 9303508
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S121-7
references.pmid: 12407585
references.citation: J Hepatol. 2003 Nov;39(5):843-9
references.pmid: 14568269
references.citation: Intern Med. 2007;46(8):473-6
references.pmid: 17443037
references.citation: World J Gastroenterol. 2006 Nov 14;12(42):6861-4
references.pmid: 17106937
references.citation: Aliment Pharmacol Ther. 2001 Apr;15(4):551-7
references.pmid: 11284785
references.citation: World J Gastroenterol. 2007 Jan 28;13(4):579-84
references.pmid: 17278224
references.citation: Hepatology. 1998 Apr;27(4):1136-43
references.pmid: 9537455
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: J Gastroenterol. 2002;37(9):732-6
references.pmid: 12375147
references.citation: Semin Oncol. 1997 Jun;24(3 Suppl 9):S9-4-S9-17
references.pmid: 9208870
references.citation: Dig Dis Sci. 2005 Apr;50(4):727-32
references.pmid: 15844709
references.citation: J Gastroenterol Hepatol. 2000 Oct;15(10):1165-70
references.pmid: 11106097
references.citation: Hepatol Res. 2001 Mar 26;19(3):284-293
references.pmid: 11251311
references.citation: Hepatology. 1999 Aug;30(2):562-6
references.pmid: 10421669
references.citation: Can J Gastroenterol. 2003 Aug;17(8):479-82
references.pmid: 12945008